Director Buys BLCO 4,300 Shares for $77,000Bausch + Lomb (BLCO 0.82%), a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity.Alfonso Eduardo, Director at Bausch + Lomb, reported an open-market purchase of 4,300 common shares for a total consideration of approximately $77,000, according to the SEC Form 4 filing.Transaction summaryMetricValueShares traded4,300Transaction value~$77,000Post-transaction shares (direct)13,855Post-transaction shares ...

PresentationLarry BiegelsenWells Fargo Securities, LLC, Research Division Good afternoon. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. Welcome to the next call in our 2026 MedTech Innovation Spotlight Call Series. I'm pleased to have the management team from Bausch + Lomb. Speakers for this call will include Dr. Yehia Hashad, Executive Vice President of R&D and Chief Medical Officer; Dr. Mayssa Attar, Senior Vice President of Pharmaceuticals and Consumer R&D; Dr. Kelly Swaim, Senior Vice ...

Bausch + Lomb (NYSE:BLCO) Update / briefing March 23, 2026 01:30 PM ET Company ParticipantsBrent Saunders - Chairman and CEOCathleen McCabe - Strategic Medical AdvisorKelly Swaim - SVP of Surgical R&DMayssa Attar - SVP of Pharmaceuticals and Consumer R&DYehia Hashad - EVP of R&D and Chief Medical OfficerConference Call ParticipantsLarry Biegelsen - Medical Device AnalystLarry BiegelsenGood afternoon. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. Welcome to the next call in our 2026 MedTech ...

BL1107 FIRST GLAUCOMA THERAPY TO IMPROVE VISUAL FUNCTION THROUGH NEUROPROTECTION ELIOS FIRST CLINICIALLY VALIDATED IMPLANT-FREE MIGS EXCIMER LASER Disclaimers Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements our focus on pipeline innovation, the success of our pipeline products and R&D programs, the existence of potential ga ...

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation, (“BLCO" or the "Company") (NYSE:BLCO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/bausch-lomb-corporation. The Portnoy ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in†webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hasha. ...

Core Insights - Bausch + Lomb Corporation reported record financial results for Q4 2025, with revenue increasing by 7% to $1.405 billion and adjusted EBITDA rising by 27% to $330 million, contributing to a full-year revenue of $5.101 billion driven by a diversified portfolio [1][3] Financial Performance - The pharmaceutical segment experienced a 14% growth in Q4, while the Vision Care division, bolstered by an 8% increase in contact lens sales, generated $778 million in revenue for the quarter [1] - The dry eye treatment Miebo was a standout performer, with Q4 revenue soaring by 111% to $112 million, attributed to marketing investments and a strong sales force [2] - The surgical segment achieved a 20% growth in premium intraocular lenses, recovering from a previous product recall [2] Future Outlook - For 2026, the company aims to maintain its adjusted EBITDA margin at 23.5% through operational execution and financial discipline, despite competitive pressures in the IOL and contact lens markets [4] - Bausch + Lomb anticipates continued outperformance of its daily SiHy lenses in the global market and expects mid-single-digit sales growth for Xiidra as net pricing stabilizes [4] Company Overview - Bausch + Lomb operates in the eye health sector across multiple countries, including the US, Canada, and various international markets, with three main segments: Vision Care, Pharmaceuticals, and Surgical [5]

Core Viewpoint - Bausch + Lomb (BLCO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements [4][6]. - For Bausch + Lomb, the recent upgrade reflects an improvement in the company's underlying business, likely leading to increased stock prices due to investor confidence [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2026, Bausch + Lomb is expected to earn $0.80 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Bausch + Lomb's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Intellectual Property and Regulatory Exclusivity - The company owns or exclusively licenses approximately 2,499 granted patents worldwide, with about 476 being U.S. patents[50]. - Approximately 83% of the issued patents are set to expire within the next 10 years, with 22 patents expiring in 2026, 37 in 2027, and 26 in 2028[50]. - The company relies on a combination of regulatory and patent rights to protect the value of its product investments[49]. - The U.S. Hatch-Waxman Act provides five years of non-patent regulatory exclusivity from the first FDA approval of a new drug compound[52]. - In the EU, a similar data exclusivity scheme allows the pioneer drug company to use data obtained at its expense for up to eight years from the first approval[53]. - The Biologics Price Competition and Innovation Act grants 12 years of market exclusivity for reference biological products[55]. - The Orphan Drug Act allows for seven years of marketing exclusivity for the first approved orphan drug for a rare disease[56]. - Canada provides an eight-year data exclusivity period for innovative drugs from the date of market approval[58]. Compliance and Regulatory Challenges - Compliance with extensive government regulations is required for the research, development, and marketing of pharmaceutical products and medical devices[61]. - The company is subject to extensive U.S. federal and state health care marketing regulations, including the federal False Claims Act, which imposes civil and criminal liability for false claims[68]. - The Physician Payment Sunshine Act requires pharmaceutical companies to report any "transfer of value" to prescribers, with significant penalties for non-compliance[69]. - The company must comply with the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws, which could result in criminal or civil penalties for violations[70]. - Compliance with the Health Insurance Portability and Accountability Act (HIPAA) is mandatory, requiring safeguards for the protection of sensitive health information[71]. - The California Consumer Privacy Act (CCPA) imposes stringent data privacy requirements, including civil penalties for violations and a private right of action for data breaches[73]. - The General Data Protection Regulation (GDPR) allows for fines of up to 4% of global annual revenue or €20 million for certain violations, significantly impacting data processing practices[75]. - The company faces compliance challenges due to differing interpretations of data protection laws in the EU and the UK, which may lead to increased operational costs[76]. - The Personal Information Protection Law (PIPL) in China imposes specific requirements for transferring personal data outside the country, affecting international operations[81]. - The company must navigate various state and federal laws regulating artificial intelligence (AI), which could require substantial changes to AI practices and incur compliance costs[78]. Market and Financial Considerations - Successful commercialization of products may depend on government and third-party payor reimbursement, with increasing pressures to limit or regulate prices in key markets[83]. - The Inflation Reduction Act (IRA) imposes financial penalties on drug price increases exceeding inflation rates, with Medicare Part D redesign starting in 2025, capping out-of-pocket costs at $2,000 for beneficiaries[87]. - Approximately 37% of the company's product sales for 2025 are produced, in total or in part, by third-party manufacturers under manufacturing arrangements[107]. - The company has a global commercial team of approximately 4,200 employees, with around 1,050 dedicated to the U.S. market for contact lenses, lens care, and pharmaceuticals[96][97]. - Customers accounting for 10% or more of total revenues include McKesson Corporation and Cardinal Health, each contributing 10% in 2025[100]. - The company operates 25 manufacturing facilities across 11 countries, focusing on specific product categories to meet regulatory requirements[103]. - As of December 31, 2025, the company employed approximately 13,000 individuals, with 7,000 in production and 900 in R&D[110]. - Legislative efforts at both federal and state levels continue to propose changes affecting drug pricing and reimbursement methodologies, potentially impacting the company's operations[88]. Employee Relations and Corporate Initiatives - The company is developing an integrated ESG program to comply with evolving regulations, including the EU's Corporate Sustainability Reporting Directive[94]. - The company has not experienced significant labor disruptions, maintaining good relations with employees and collective bargaining in some regions[111]. - The company anticipates ongoing macroeconomic challenges affecting inflation and supply chains, which its global supply team is actively managing[109]. - In 2025, the company achieved an annual Days Away Rate (DAR) of 5.5, meeting its goal of not exceeding 6, significantly lower than the industry standard DAR of 22[113]. - The company launched the Bausch + Lomb AI Academy in 2025, providing employees with access to world-class AI courses tailored for all experience levels[119]. - The company implemented a women's health program in the United States in 2025, providing comprehensive support for various health-related issues[121]. - The ONE by ONE Recycling Program has collected over 114 million used contact lenses and related items since its launch in November 2016[123]. - The company’s revenues are historically weighted toward the second half of the year, with first-quarter sales typically lower due to patient co-pays and deductibles resetting[124]. - The company has a robust global succession planning process to identify and develop talent for critical leadership positions[120]. - The company’s total rewards philosophy includes base pay, short-term and long-term incentives, aimed at attracting and retaining employees[121]. Financial Position and Risk Management - As of December 31, 2025, the company had $3,695 million in variable rate debt and $1,412 million in fixed rate debt, with a €675 million principal amount requiring repayment in Euros[599]. - A 100 basis-point change in interest rates would have an annualized pre-tax effect of approximately $37 million on the company's earnings and cash flows[599]. - A 1% change in foreign currency exchange rates would have impacted the company's shareholders' equity by approximately $23 million as of December 31, 2025[598].

Core Viewpoint - Bausch + Lomb's CEO Brent Saunders emphasizes the necessity for employees to learn AI to remain competitive and relevant in the industry, linking AI training to bonuses as a strategy to modernize the company [1][2][8]. Financial Performance - The company reported Q4 revenue of $1.4 billion, reflecting a 10% year-over-year increase and surpassing forecasts of $1.38 billion [3]. - Adjusted EPS was $0.32, which fell short of consensus estimates of $0.36 [3]. - Full-year revenue reached $5.1 billion, with a cautious outlook projecting revenue between $5.375 billion and $5.475 billion for 2026 [3]. Stock Performance - Following the fourth quarter results, Bausch + Lomb's shares declined by 2%, although the stock has increased by 6% over the past year, underperforming the S&P 500's 13% rise [2]. Strategic Initiatives - The company is implementing mandatory AI training for employees, aiming to enhance their skills and application of AI in their roles [2][4]. - This initiative is seen as a potential efficiency booster that the market has not yet fully recognized [4]. Industry Context - Saunders compares the current AI revolution to the advent of the internet and mobile technology, suggesting that AI could be one of the most significant technologies of this era [6]. - The company is navigating a substantial debt load and the aftermath of its 2022 spin-off from Bausch Health, making execution critical [5]. Future Considerations - Investors are advised to monitor the "net price" of the AI initiative, particularly its impact on R&D and administrative costs, which could lead to more affordable medicines [9].